HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Wellness New Product Roundup: 'The Truth' CBD, Hilo Performance Gummies, Syntech Offers More In US

Executive Summary

Wakunaga expands Kyo-Dophilus probiotic line; Avadim Health's Theraworx reaches pharmacies; Naturade expands VeganSmart line; Goodbye UTI supplement contains d-mannose; Hilo Nutrition workout gummies alternative to powders, liquids; Syntech Nutrition adds to US distribution; and former NBA great Paul Pierce enters wellness business with cannabidiol oils, vaporizers.

You may also be interested in...



FDA Decision On CBD Use Could Run Up Against Chicken Or Egg Question

Speakers at FDA's first-ever public hearing on using cannabis-derived ingredients in products subject to its oversight asked agency officials to look back further than history of drug research with cannabinoids to earlier than the origin of its regulations as it considers its decision. "CBD is a constituent inherent in hemp which has been marketed and used at least since the Civil War," says cannabis business attorney Rob Kight.

Health, Beauty And Wellness News: Nutrisystem Adds Options, Roar Gains $5.6M, SynTech Elite In US, More News

Nurtisystem launches FreshStart, South Beach Keto; Roar Beverage $5.6m funding led by AccelFoods; SynTech brings Elite Series to US; ChromaDex extends Tru Niagen to Canada with Fullscript; Nugenix Sexual Vitality Booster with Nitrosigine; Abattis debuts Vergence Naturals with Comfort; Brueggman takes Vitaquest helm; and CBD Bath Soaks from allitom.

Roche Continues To Make The Case For Gantenerumab In Alzheimer’s Disease

The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.

Topics

UsernamePublicRestriction

Register

RS148991

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel